Related Experiment Video

Updated: Jun 20, 2025

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

25.8K

From Challenge to Opportunity: How Shwachman-Diamond Syndrome Became a Promising Target for Therapy Development

Eszter S Hars1, Lisa J McReynolds2

  • 1Shwachman-Diamond Syndrome Alliance Inc, Woburn, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|July 22, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Experiment Videos

Last Updated: Jun 20, 2025

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

25.8K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K

Articles linked to this work by shared authors, journal, and citation graph.

Genomic ascertainment of PALB2-related cancer predisposition: PALB2-related cancer predisposition.

medRxiv : the preprint server for health sciences·2026

Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy.

Blood advances·2026

Identification of biallelic POLA2 variants in two families with an autosomal recessive telomere biology disorder.

European journal of human genetics : EJHG·2024

Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.

Leukemia·2024

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations.

Blood·2024

Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Probabilistic Risk-Benefit Profile of Ticagrelor Monotherapy After Short Dual Antiplatelet Therapy: A Bayesian Analysis of the ULTIMATE-DAPT Trial.

Clinical pharmacology and therapeutics·2026

From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs.

Clinical pharmacology and therapeutics·2026

Advancing Regulatory Adoption of New Approach Methodologies.

Clinical pharmacology and therapeutics·2026

Perspective on Pharmacokinetic Comparability for Biologics Development.

Clinical pharmacology and therapeutics·2026

Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.

Clinical pharmacology and therapeutics·2026

Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer.

Clinical pharmacology and therapeutics·2026

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

British journal of haematology·2026

Tat-dependent protein translocation and its evolution.

FEMS microbiology reviews·2026

Theranostics in the management of prostate cancer: from concept to clinical practice.

Expert review of clinical pharmacology·2026

miR-324-5p acts as an independent prognostic biomarker and inhibits pediatric medulloblastoma progression by targeting HOXA9.

Nucleosides, nucleotides & nucleic acids·2026

Th1-biased iNKT cell agonist-loaded liposomal peptide vaccines synergize with a PD-L1 inhibitor to boost immunotherapy against gastric cancer.

Chemical communications (Cambridge, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us